phenylhydrazonopyrazolone sulfonate 1 (PHPS1), an SHP2 inhibitor, inhibits the expression of IFN‐γ, TNF‐α, and matrix metalloproteinases while increasing the expression of IL‐10 and Arg‐1, inducing macrophage polarization toward the M2 type, thereby attenuating AAA progression. Here, TNF is linked to triple-A syndrome.